用HepaSH单层预测人类肝脏清除,用于低周转率化合物
Shotaro Uehara1, Yuichiro Higuchi1, Nao Yoneda1
1Liver Engineering Laboratory, Department of Research for Humanized Model, Central Institute for Experimental Medicine and Life Science, Kanagawa, Japan.
Drug metabolism and disposition: the biological fate of chemicals
|December 3, 2025
概括
长期培养的高功能HepaSH细胞改善了药物清除预测. 这种稳定的体外系统准确地监测低周转率的化合物,有助于药物开发的药理动力学特征.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
- 在体外毒理学中
背景情况:
- 初级悬浮肝细胞对于药物药理动力学至关重要,但其稳定性不佳,限制了低代谢周转率化合物的体外检测.
- 传统的体外试验方法难以准确评估缓慢代谢率的化合物的药物清除.
研究的目的:
- 评估长期HepaSH细胞培养系统对预测各种药物的肝清除的有用性.
- 在扩展单层培养中评估HepaSH细胞的稳定性和药物代谢活性.
主要方法:
- 在单层培养中使用了来自人性化模拟老鼠肝脏的HepaSH细胞,长达168小时.
- 化12种具有不同内在清除 (CLint) 值的药物与HepaSH单层一起监测化合物耗尽.
- 将预测的肝清除值与临床参考数据进行比较.
主要成果:
- 肝炎SH单层维持了细胞染色体P450活性和形态168小时,没有改变介质.
- 成功监测了低和中等至高CLint药物的耗尽,包括迪亚泽巴姆,氨酸和米达佐拉姆.
- 12种药物中的6-8种药物的预测肝清除在3倍偏差范围内,平均折叠误差在1.14-1.97之间.
结论:
- 稳定的HepaSH单层培养系统通过延长代谢反应时间有效评估低清除化合物.
- 这种方法为新药候选药物的药理动力学特征提供了有价值的工具,特别是那些循环缓慢的药物.
- 对于极低清除药物,如迪索皮拉米德和华法林,观察到局限性,表明需要进一步改进方法的领域.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
250
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
250
Hepatic Drug Clearance: Effect of Protein Binding
497
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
497
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
457
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Most drugs undergo restrictive clearance, which is proportional to the...
457
Hepatic Drug Clearance: Role of Transporters
284
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
284
One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance
327
Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...
327
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
196
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
196


